PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 21, 2026BMC Women s Health3 citationsOpen Access

Fertility-preserving treatment for endometrial atypical hyperplasia and endometrial cancer: a systematic review and meta-analysis

JYJiatian YeXQXinyi QiuXQXiaorong Qi

Key Points

  • The aim is to evaluate the effectiveness of progestin-based fertility-preserving treatments in women with endometrial cancer and atypical hyperplasia.
  • Conducted a systematic review and meta-analysis of relevant studies published until April 2025.
  • Included 54 studies with a total of 2148 endometrial cancer and 1418 atypical hyperplasia patients.
  • Utilized random-effects model and Newcastle-Ottawa Scale for quality assessment.
  • Primary outcomes measured included complete response, pregnancy rate, and live birth rate.
  • 78% of endometrial cancer patients achieved complete response, with LNG-IUD alone showing the highest rate at 85%.
  • 60% of those who achieved complete response went on to have clinical pregnancies, while 57% had live deliveries.
  • For atypical hyperplasia, 87% achieved complete response, with 48% achieving pregnancy and 37% live delivery.
  • About 33% of endometrial cancer patients and 22% of atypical hyperplasia patients experienced relapse.

Abstract

The incidence of endometrial cancer is rising, especially among younger women. Given the strong need to preserve fertility, robust evidence is required to evaluate the effectiveness of progestin-based fertility-preserving treatment regimens. We conducted a systematic review and meta-analysis to summarize the oncological and reproductive outcomes of patients with endometrial cancer (EC) and endometrial atypical hyperplasia patients (EAH) undergoing progestin-based therapies, and to compare outcomes across different fertility-preserving treatment regimens. We searched PubMed and EMBASE to identify relevant studies published online up to 2 Apr 2025. This proportional meta-analysis was performed using a random-effects model to combine the data. A checklist based on the Newcastle-Ottawa Scale and the Methodological Index for Non-randomized Studies was used for quality assessment. The primary outcomes for this meta-analysis were complete response, pregnancy rate, and live birth rate following fertility-preserving treatment in patients with EC or AH. The secondary outcomes are was the recurrence rate (RR). Cochran’s Q test and I2 were used to evaluate the degree of heterogeneity of eligible studies. Sensitivity analyses were performed with the leave-one-out strategy. Publication bias was assessed using funnel plots and Egger’s test. Of 1332 identified studies, 54 were included in the final analysis. Including 2148 patients with endometrial cancer and 1418 with endometrial atypical hyperplasia. For patients with EC, 78% achieved complete response (CR). Patients treated with LNG-IUD alone had the highest CR rate (85%). Among patients who achieved CR and contempt to conceive, 60% achieved clinical pregnancy and 57% achieved live delivery. While about 1/3 patients will undergoing relapse (33%). For patients with EAH, 87% achieved CR, 48% achieved pregnancy and 37% achieved live delivery, while approximately one-fifth experienced relapse (22%). Sensitivity analysis demonstrated robust results. Different progestin-based therapy regimens are effective for fertility preservation in patients with EC and EAH. The results of this meta-analysis may inform clinical management and support personalized treatment decisions.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Ye et al. (2026) studied this question.

synapsesocial.com/papers/69994c80873532290d020ff6https://doi.org/10.1186/s12905-026-04352-y
Ask AI
Helpful
Bookmark
Share
View Full Paper